Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352244 | 0.87 | MAOA (0.52) | KDM4EGPR3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL21235343 | 0.83 | NFATC1 (0.40) | KDM4EGPR3MEN1TSHRMAPK1 | |
| SCHEMBL6671902 | 0.79 | MAPT (0.48) | KDM4EMAPTSMN1; SMN2MEN1TP53 | |
| SCHEMBL18161800 | 0.77 | KDM4E (0.32) | KDM4EGPR3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL15333391 | 0.75 | ACHE (0.47) | KDM4EGPR3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL2515607 | 0.73 | MAPK8 (0.50) | MAPTCYP2C9MAPK1CYP2C19KMT2A | |
| SCHEMBL18416164 | 0.71 | GABRP (0.36) | KDM4EMAPTSMN1; SMN2MEN1TP53 | |
| SCHEMBL16369461 | 0.71 | GABRP (0.40) | KDM4EMAPTSMN1; SMN2MEN1TP53 | |
| SCHEMBL29997743 | 0.71 | GPR3 (0.48) | KDM4EGPR3MAPTSMN1; SMN2BCHE | |
| SCHEMBL4071981 | 0.70 | NPC1 (0.44) | KDM4EMAPTSMN1; SMN2MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0713870-B1 | NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-07-18 | — | — | EP | claimed |
| EP-0713870-A1 | NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-05-29 | — | — | EP | claimed |
| US-20230380280-A1 | ORGANIC COMPOUNDS, MIXTURES AND APPLICATIONS THEREOF IN ORGANIC ELECTRONIC DEVICES | Zhejiang Brilliant Optoelectronic Technology Co.,Ltd. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230357169-A1 | ORGANIC COMPOUNDS, MIXTURES, AND USES THEREOF IN ORGANIC ELETRONIC DEVICES | Zhejiang Brilliant Optoelectronic Technology Co.,Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-11680059-B2 | Organic mixture and application thereof in organic electronic devices | GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| US-11674080-B2 | Transition metal complex, polymer, mixture, formulation and use thereof | GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-02-24 | — | — | US | disclosed |
| US-20200317646-A1 | ORGANIC MIXTURE AND APPLICATION THEREOF IN ORGANIC ELECTRONIC DEVICES | GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| EP-0713870-B1 | NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-07-18 | — | — | EP | disclosed |
| US-6028079-A | FOR TREATING TUMOR OF MAMMAL | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0713870-A1 | NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357169-A1 | ORGANIC COMPOUNDS, MIXTURES, AND USES THEREOF IN ORGANIC ELETRONIC DEVICES | SLCO1B3, SLCO2B1, SLCO2A1 | KDM4E 3380/4885GPR3 3694/4885MAPT 1108/4885 |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | KDM4E 911/4885GPR3 3074/4885MAPT 4269/4885 |
| US-11674080-B2 | Transition metal complex, polymer, mixture, formulation and use thereof | OPRD1, OCIAD1, OCIAD2 | KDM4E 3827/4885GPR3 1281/4885MAPT 1806/4885 |
| US-20200317646-A1 | ORGANIC MIXTURE AND APPLICATION THEREOF IN ORGANIC ELECTRONIC DEVICES | OCIAD1, OCIAD2, SORD | KDM4E 4426/4885GPR3 1981/4885MAPT 1084/4885 |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | KDM4E 911/4885GPR3 3074/4885MAPT 4269/4885 |
| US-20230380280-A1 | ORGANIC COMPOUNDS, MIXTURES AND APPLICATIONS THEREOF IN ORGANIC ELECTRONIC DEVICES | OR10J3, AOX1, SLCO4C1 | KDM4E 3730/4885GPR3 2958/4885MAPT 1171/4885 |
| US-11680059-B2 | Organic mixture and application thereof in organic electronic devices | OCIAD1, OCIAD2, SORD | KDM4E 4426/4885GPR3 1981/4885MAPT 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.